EP3558902A4 - METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS - Google Patents

METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS Download PDF

Info

Publication number
EP3558902A4
EP3558902A4 EP17882736.6A EP17882736A EP3558902A4 EP 3558902 A4 EP3558902 A4 EP 3558902A4 EP 17882736 A EP17882736 A EP 17882736A EP 3558902 A4 EP3558902 A4 EP 3558902A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
pharmaceutical compounds
substituted porphyrin
making substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17882736.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3558902A1 (en
Inventor
Ines Batinic-Haberle
Artak TOVMASYAN
Zrinka Rajic DZOLIC
Ivan Spasojevic
Christopher Allen LEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomimetix Jv LLC
Duke University
Original Assignee
Biomimetix Jv LLC
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomimetix Jv LLC, Duke University filed Critical Biomimetix Jv LLC
Publication of EP3558902A1 publication Critical patent/EP3558902A1/en
Publication of EP3558902A4 publication Critical patent/EP3558902A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B47/00—Formation or introduction of functional groups not provided for in groups C07B39/00 - C07B45/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EP17882736.6A 2016-12-20 2017-12-19 METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS Withdrawn EP3558902A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436743P 2016-12-20 2016-12-20
PCT/US2017/067263 WO2018118891A1 (en) 2016-12-20 2017-12-19 Methods of making substituted porphyrin pharmaceutical compounds and compositions

Publications (2)

Publication Number Publication Date
EP3558902A1 EP3558902A1 (en) 2019-10-30
EP3558902A4 true EP3558902A4 (en) 2020-06-24

Family

ID=62628012

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17882736.6A Withdrawn EP3558902A4 (en) 2016-12-20 2017-12-19 METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS

Country Status (8)

Country Link
US (1) US20190330220A1 (enExample)
EP (1) EP3558902A4 (enExample)
JP (1) JP2020502280A (enExample)
KR (1) KR20190098211A (enExample)
CN (1) CN110291060A (enExample)
CA (1) CA3046357A1 (enExample)
MX (1) MX2019007301A (enExample)
WO (1) WO2018118891A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187411A1 (en) * 2017-04-04 2018-10-11 Biomimetix Jv, Llc Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure
WO2019067523A1 (en) * 2017-09-29 2019-04-04 Duke University FLUOROSUBSTITUTED PORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF PREPARATION AND USE THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077269A1 (en) * 2004-02-09 2005-08-25 Duke University Substituted porphyrins
WO2010138633A1 (en) * 2009-05-26 2010-12-02 Duke University Method of providing neuroprotection using substituted porphyrins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US20110275606A1 (en) * 2009-01-07 2011-11-10 Duke University Substituted porphyrins
US10080759B2 (en) * 2014-01-22 2018-09-25 Duke University Methods of treating pruritus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077269A1 (en) * 2004-02-09 2005-08-25 Duke University Substituted porphyrins
WO2010138633A1 (en) * 2009-05-26 2010-12-02 Duke University Method of providing neuroprotection using substituted porphyrins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BATINIC-HABERLE INES ET AL: "Manganese(iii) meso-tetrakis(ortho-N-alkylpyridyl)porphyrins. Synthesis, characterization, and catalysis of O2˙- dismutation", JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS., no. 13, 7 June 2002 (2002-06-07), GB, pages 2689 - 2696, XP055790365, ISSN: 1472-7773, DOI: 10.1039/b201057g *
See also references of WO2018118891A1 *
TOVMASYAN ARTAK ET AL: "Anticancer therapeutic potential of Mn porphyrin/ascorbate system", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER INC, US, vol. 89, 20 October 2015 (2015-10-20), pages 1231 - 1247, XP029334836, ISSN: 0891-5849, DOI: 10.1016/J.FREERADBIOMED.2015.10.416 *
ZRINKA RAJIC ET AL: "A new SOD mimic, Mn(III)-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER INC, US, vol. 52, no. 9, 3 February 2012 (2012-02-03), pages 1828 - 1834, XP028421078, ISSN: 0891-5849, [retrieved on 20120213], DOI: 10.1016/J.FREERADBIOMED.2012.02.006 *

Also Published As

Publication number Publication date
KR20190098211A (ko) 2019-08-21
US20190330220A1 (en) 2019-10-31
CA3046357A1 (en) 2018-06-28
CN110291060A (zh) 2019-09-27
EP3558902A1 (en) 2019-10-30
JP2020502280A (ja) 2020-01-23
WO2018118891A1 (en) 2018-06-28
MX2019007301A (es) 2019-10-30

Similar Documents

Publication Publication Date Title
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3151839A4 (en) Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
EP3116492A4 (en) Pharmaceutical compositions of therapeutically active compounds
EP3102555A4 (en) Compositions of compounds and uses thereof
EP3116511A4 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3582777A4 (en) PHARMACEUTICAL COMPOSITION OF APIXABAN
EP3116491A4 (en) Pharmaceutical compositions of therapeutically active compounds
EP3253403A4 (en) Methods and compositions for improved cognition
EP3429589A4 (en) PHARMACEUTICAL COMPOSITION OF NILOTINIB
ZA201807125B (en) Pharmaceutical composition of dapagliflozin
EP3399996A4 (en) METHOD FOR THE ADMINISTRATION OF HEPCIDINE
EP3202759A4 (en) Alpha-aminoamide derivative compound and pharmaceutical composition comprising same
EP3148645A4 (en) Oral pharmaceutical composition of isotretinoin
EP3493808A4 (en) PHARMACEUTICAL COMPOSITIONS OF IBRUTINIB
EP3302412A4 (en) PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN FOR ORAL INJECTION ONCE DAILY
EP3183243A4 (en) Organotellurium compounds, compositions and methods of use thereof
EP3509614A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LAFORA DISEASE
EP3532055A4 (en) COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF COMPOUNDS
EP3532052A4 (en) DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS
EP3148644A4 (en) Oral pharmaceutical composition of isotretinoin
EP3174601A4 (en) Oral pharmaceutical composition of isotretinoin
EP3231423A4 (en) Pharmaceutical composition of polyethylene glycol-modified camptothecin derivative and preparation method therefor
EP3203992A4 (en) Compositions and methods for increasing the bioavailability of one or more compounds
EP3302438A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN
EP3171860A4 (en) Solid oral formulation of fenretinide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200525

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20200516BHEP

Ipc: C07D 487/22 20060101AFI20200516BHEP

Ipc: A61P 7/06 20060101ALI20200516BHEP

Ipc: A61P 25/00 20060101ALI20200516BHEP

Ipc: A61K 31/409 20060101ALI20200516BHEP

Ipc: A61P 29/00 20060101ALI20200516BHEP

Ipc: A61P 35/00 20060101ALI20200516BHEP

Ipc: A61P 3/10 20060101ALI20200516BHEP

Ipc: A61P 9/00 20060101ALI20200516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220414